Overview
Bifidobacterium animalis subsp. lactis is a Gram-positive, anaerobic, rod-shaped bacterium of the phylum Actinobacteria, family Bifidobacteriaceae. It is one of the most commercially important and scientifically studied probiotic organisms in the world, used extensively in fermented dairy products, dietary supplements, and infant formulas. For a general overview of the species, see the companion entry on Bifidobacterium lactis, which covers shared characteristics and the taxonomic relationship between B. lactis and B. animalis.
This entry focuses on the subspecies-level classification and the three major commercial strains that have defined the clinical evidence base: BB-12, HN019, and DN-173 010 (marketed as Activia).
Taxonomic Clarification
The naming history of this organism has been a source of confusion in both scientific and commercial contexts:
- Original classification: The organism was initially described as a separate species, "Bifidobacterium lactis," by Meile et al. in 1997
- Reclassification: Subsequent DNA-DNA hybridization and 16S rRNA gene sequencing studies demonstrated that B. lactis was in fact a subspecies of B. animalis, leading to the revised nomenclature Bifidobacterium animalis subsp. lactis
- Commercial usage: Many probiotic products continue to use the name "B. lactis" for simplicity, though "B. animalis subsp. lactis" is the taxonomically correct designation
- Functional distinction: The subspecies lactis is distinguished from B. animalis subsp. animalis by its adaptation to the dairy environment, higher oxygen tolerance, and extensive use in human probiotic applications
Both names — B. lactis and B. animalis subsp. lactis — refer to the same organism. When evaluating probiotic products or research, the strain designation (e.g., BB-12, HN019) is more informative than the species name alone.
Key Commercial Strains
BB-12 (Chr. Hansen)
BB-12 is widely regarded as one of the most documented probiotic strains in the world, with over 300 published scientific studies as of 2024.[1]
Primary clinical applications:
- Immune support: Enhanced influenza vaccine response in healthy adults, with significantly higher vaccine-specific IgG and IgA antibodies compared to placebo
- Infant health: Improved intestinal antibody responses (anti-poliovirus and anti-rotavirus IgA) in formula-fed infants; reduced risk of respiratory infections during early infancy
- Digestive regularity: Significant increase in defecation frequency in adults with low baseline bowel movement frequency
- Antibiotic-associated diarrhea: When combined with Lactobacillus acidophilus La-5, reduced diarrhea duration and severity in adults on antibiotic therapy
BB-12 is characterized by excellent technological properties including high oxygen tolerance, acid resistance, and bile tolerance, making it one of the most stable strains for commercial production. It has been used in clinical trials spanning neonates through to the elderly, with a consistently favorable safety profile.[1]
HN019 (Fonterra / DuPont Danisco)
HN019 (also designated DR10) was originally isolated from fermented dairy products in New Zealand and has been studied primarily for its effects on immune function and gut transit.
Primary clinical applications:
- Immune enhancement in the elderly: In a landmark study, Gill et al. (2001) demonstrated that daily consumption of HN019 by healthy elderly subjects (aged 63-84) significantly enhanced both polymorphonuclear (PMN) cell phagocytic activity and natural killer (NK) cell tumor-killing activity in a dose-dependent manner.[2] These improvements were most pronounced in subjects with the poorest baseline immune function.
- Gut transit time: Waller et al. (2011) showed that HN019 reduced whole gut transit time in a dose-dependent manner in healthy adults. The high-dose group (17.2 billion CFU/day) experienced a mean reduction of 31 hours (from 49 to 21 hours), while the low-dose group (1.8 billion CFU/day) showed a 23-hour reduction.[3] Significant improvements were also observed in functional gastrointestinal symptoms including constipation, irregular bowel movements, and flatulence.
- Cellular immune function: A systematic review and meta-analysis confirmed that HN019 supplementation significantly enhances PMN phagocytic capacity and NK cell tumoricidal activity, with the greatest benefits observed in elderly subjects with compromised baseline immunity.[4]
DN-173 010 (Danone / Activia)
DN-173 010, marketed under the brand name Activia, is one of the most widely consumed probiotic strains globally. It is delivered in a fermented dairy matrix alongside the traditional yogurt cultures S. thermophilus and L. bulgaricus.
Primary clinical applications:
- Gut transit time: DN-173 010 has been shown to reduce colonic transit time, particularly the sigmoid transit time, in both healthy adults and individuals with IBS-constipation[5]
- IBS symptom relief: Guyonnet et al. (2007) conducted a randomized, double-blind, placebo-controlled trial in 274 adults with IBS and demonstrated that DN-173 010 consumption significantly improved health-related quality of life and reduced the composite score of digestive symptoms, with the most pronounced benefits observed in the constipation-predominant subgroup.[6]
- Abdominal distension: In IBS-C patients, DN-173 010 significantly reduced abdominal distension compared to a non-fermented dairy control, with measurable improvements in abdominal girth assessed by physical measurement[5]
It should be noted that European Food Safety Authority (EFSA) rejected specific health claims for Activia related to digestive comfort, citing insufficient evidence to establish a cause-and-effect relationship for the general population. This regulatory decision illustrates the high evidentiary bar required for probiotic health claims in Europe, even for well-studied strains.
Mechanisms of Action
The clinical effects observed across BB-12, HN019, and DN-173 010 are supported by several mechanistic pathways:
Immune Modulation
- Enhancement of phagocytic activity of polymorphonuclear cells and monocytes
- Increased natural killer cell tumoricidal activity
- Stimulation of mucosal IgA production
- Modulation of dendritic cell maturation and cytokine profiles (IL-10, IL-12, TNF-alpha)
Gut Motility and Transit
- Production of short-chain fatty acids (primarily acetate and lactate) that lower colonic pH and may stimulate intestinal smooth muscle contraction
- Possible modulation of serotonin signaling in the enteric nervous system
- Alteration of gas production patterns, potentially reducing abdominal distension
Microbiota Modulation
- Competitive exclusion of pathogenic organisms through adhesion to intestinal epithelial cells
- Production of organic acids that create an unfavorable environment for many pathogens
- Cross-feeding relationships with other beneficial bacteria, including butyrate producers
Strain-Specificity: A Critical Consideration
One of the most important principles in probiotic science is that clinical effects are strain-specific. While BB-12, HN019, and DN-173 010 all belong to the same subspecies, they have distinct clinical profiles:
| Feature | BB-12 | HN019 | DN-173 010 |
|---|---|---|---|
| Primary strength | Immune & infant health | Immune function in elderly | Gut transit & IBS |
| Research volume | 300+ publications | 50+ publications | 30+ clinical trials |
| Key populations | Infants through elderly | Elderly | Adults with IBS/constipation |
| Delivery format | Supplements, infant formula | Supplements, dairy | Fermented dairy (Activia) |
Consumers and healthcare providers should select strains based on the specific health outcome desired, rather than assuming that all B. animalis subsp. lactis strains are interchangeable.
Safety Profile
B. animalis subsp. lactis has an excellent safety record across all major commercial strains. It holds GRAS status in the United States and QPS status in Europe. Clinical trials have been conducted in vulnerable populations including premature infants, newborns, the elderly, and immunocompromised individuals without significant safety concerns. The subspecies has been consumed globally in fermented dairy products for decades without reports of systemic infection or other serious adverse events.
Key Takeaways
- B. animalis subsp. lactis is taxonomically the same organism as "B. lactis" — the subspecies designation is the formally correct name
- Three major commercial strains (BB-12, HN019, DN-173 010) dominate the clinical evidence base, each with distinct therapeutic profiles
- BB-12 is among the world's most documented probiotic strains, with strong evidence for immune function and infant health
- HN019 shows particular promise for immune enhancement in elderly populations and reducing gut transit time
- DN-173 010 (Activia) has the strongest evidence for gut motility and IBS-constipation symptom relief
- Probiotic effects are strain-specific; results from one strain cannot be automatically extrapolated to another within the same subspecies
- All major strains have excellent safety profiles across diverse populations